Your Daily Pharmaceuticals Briefing

Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology

• Gilead Sciences has entered a collaboration and license agreement with Vir Biotechnology, potentially valued at $1.87 billion, to discover three PRO-XTEN dual-masked T-cell engagers for solid tumors. Vir will receive $90 million upfront as part of the deal.

  PharmexecRopesgrayBiospace

• Separately, Generate Biomedicines and Zealand Pharma announced a multi-target strategic collaboration, potentially worth nearly $1.2 billion, to develop protein therapeutics for obesity and metabolic diseases. Generate will utilize its generative AI platform for research in this partnership.

  RopesgrayBiospaceFiercebiotech

• Arrowhead Pharmaceuticals reported interim Phase 1/2a clinical data for ARO-MAPT, an RNA interference (RNAi) therapeutic for Alzheimer's disease, demonstrating deep and durable reductions in cerebrospinal fluid total tau in healthy volunteers. This marks the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier via subcutaneous injection.

  Arrowheadpharma